An oral form of calcitonin has the potential to offer patients a proven therapeutic with easier administration and enhanced long-term compliance

TARSA THERAPEUTICS OVERVIEW

Tarsa Therapeutics, Inc. was founded in 2009 with the goal of developing innovative therapies for the treatment and prevention of osteoporosis and related bone diseases.  Tarsa is developing OSTORA™, an oral formulation of calcitonin—a recombinant peptide hormone that inhibits bone resorption, a key process underlying the development of osteoporosis.  Despite its 25-year history of safety and efficacy, widespread use of calcitonin has been limited by the fact that it currently is available only in injectable and intranasal formulations.  Tarsa’s unique, once-daily oral calcitonin tablet OSTORA has the potential to offer patients the proven safety and efficacy of calcitonin with the significant advantage of easier administration and enhanced long-term compliance.  Tarsa’s OSTORA has generated positive safety and efficacy data in a Phase III clinical trial. Study results were presented at the American Society for Bone and Mineral Research 2011 Annual Meeting.  Tarsa has also initiated a Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis, and patient enrollment and dosing are underway.

Tarsa licensed its oral calcitonin program with exclusive global development and commercialization rights (excluding China) from Unigene Laboratories, Inc., which manufactures a leading brand of intranasal calcitonin and is also a part owner of Tarsa.

Tarsa is located in downtown Philadelphia and has recruited an experienced team of biopharmaceutical executives.